Hypertrophic cardiomyopathy (HCM) is one
of the most common forms of genetic heart disease, affecting one in
500 people in the UK. Paul James is among them.
Existing treatments only work on the symptoms of a minority of
patients, leaving the majority with no effective treatment for
But now, thanks to a landmark research study funded by BHF, it has
been established that a relatively cheap and widely available drug
called perhexiline leads to a huge improvement in symptoms.
The results need to be double-checked in a bigger trial, but the
signs are good. For Paul, aged 53, it’s life-changing news.